Catalyst

Slingshot members are tracking this event:

GlaxoSmithKline (GSK) and Johnson & Johnson (JNJ) Plan to Submit Application to FDA in 2016 for Sirukumab in Rheumatoid Arthritis

Source Link:
http://www.gsk.com/en-gb/media/press-releases/2016/gsk-announces-eu-regulatory-submission-for-sirukumab-in-rheumatoid-arthritis/

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
REGN
100%
GSK
100%
SNY
100%
JNJ
100%
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Sep 23, 2016
Occurred Source:
http://www.businesswire.com/news/home/20160923005312/en
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Fda, New Drug Application, Sirukumab, Rheumatoid Arthritis, Sarilumab
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.